In vitro antifungal activity of fluconazole and voriconazole against non-Candida yeasts and yeast-like fungi clinical isolates.
The risk of opportunistic infections caused by non-Candida yeasts and yeast-like fungi is increasingly common, mainly in immunocompromised patients. Appropriate first-line therapy has not been defined and standardized, mainly due to the low number of cases reported. To improve empirical treatment guidelines, we describe the susceptibility profile to fluconazole and voriconazole of 176 non-Candida yeasts and yeast-like fungi collected from hospitals in Piedmont, North West Italy from January 2009 to December 2013. The results showed that most isolates are susceptible to voriconazole (94%), but less susceptible to fluconazole (78%), suggesting that voriconazole could be used as first-line therapy in infections caused by these fungi.
Department of Public Health and Paediatrics, Microbiology Division, University of Turin, Turin, Italy.
Narcisa
N
Mandras
Department of Public Health and Paediatrics, Microbiology Division, University of Turin, Turin, Italy.
Janira
J
Roana
Department of Public Health and Paediatrics, Microbiology Division, University of Turin, Turin, Italy.
Daniela
D
Scalas
Analysis Laboratory and Microbiology, C.T.O./C.R.F. Hospital, Turin, Italy.
Giacomo
G
Fucale
Department of Public Health and Paediatrics, Microbiology Division, University of Turin, Turin, Italy.
Valeria
V
Allizond
Department of Public Health and Paediatrics, Microbiology Division, University of Turin, Turin, Italy.
Giuliana
G
Banche
Microbiology Laboratory, S. Giovanni Battista Hospital, Turin, Italy.
Anna
A
Barbui
Analysis Laboratory and Microbiology, Infermi Hospital, Biella, Italy.
Nicolò
N
Li Vigni
Giles Scientific, Inc., Santa Barbara, California.
Vance A
VA
Newell
Department of Public Health and Paediatrics, Microbiology Division, University of Turin, Turin, Italy.
Anna Maria
AM
Cuffini
Department of Public Health and Paediatrics, Microbiology Division, University of Turin, Turin, Italy.
Vivian
V
Tullio
D000935:Antifungal Agents / Q000494:pharmacology*; D025141:Drug Resistance, Fungal; D015725:Fluconazole / Q000494:pharmacology*; D005658:Fungi / Q000187:drug effects* / Q000254:growth & development / Q000302:isolation & purification; D006801:Humans; D007558:Italy; D008826:Microbial Sensitivity Tests; D009181:Mycoses / Q000382:microbiology*; D065819:Voriconazole / Q000494:pharmacology*; D015003:Yeasts / Q000187:drug effects / Q000254:growth & development / Q000302:isolation & purification
D000935:Antifungal Agents; D015725:Fluconazole; D065819:Voriconazole
Fluconazole; Susceptibility testing; Voriconazole; Yeast-like fungi; Yeasts